Alkem Laboratories Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
Posted by : Ekta Dhawan | Thu Feb 12 2026
Click and Sign Up to Get Live Updates on Q3 Results
Alkem Laboratories’ Q3 results FY26 are scheduled to be announced on 13th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Alkem Laboratories Q3 Results 2026 Preview
- Alkem Laboratories’s revenue is expected to be in the range of ₹3,374.28 crore, a 1.18% YoY decrease.
- Profit After Tax, or PAT, is projected to fall 9.12% YoY.
- Net profit is ₹625.82 crore, a fall of 9.12% YoY
- EBITDA to rise 0.03%
Alkem Laboratories Share Performance
- Over the past six months, Alkem Laboratories’ share price has risen by 3.12% to ₹837.45.
- Moreover, over the past year, the stock has decreased by 4.78%.
- Despite this weak short-term performance, Alkem Laboratories’ stock has delivered a financially sound 103.91% return over the past 5 years.
- As of 12th February 2026, the stock traded at ₹837.45 per share.
About Alkem Laboratories
Alkem Laboratories is a leading Indian multinational company incorporated in 1973 and headquartered in Mumbai. Company manufactures specialty medicines includes generics, APIs and nutrachemicals and vitamins minerals products. Alkemlaboraties has a wide presence in india and across the world. The companies highly focus on the research & Development and high quality products which approves international regulatory standards and long term support in growth. Its revenue was about ₹12,964 crore. The total assets at the end of FY2025 were about ₹17,691 crore.
Key Factors to Watch for Alkem Laboratories Q3 Results FY26
- Revenue Growth & Segment Mix
To track the overall growth from indian and international market. If in domestic and exports shows a strong demand in growth than there is stability in revenue.
- Profitability & Margins
Emphasis will be on operating margins and net profits earned. The impact of raw material cost, freight cost, and marketing cost needs attention. Proper cost controls add to the profits earned.
- US & International Business Performance
The US market is an important market for Alkem. The approval of ANDAs, new product launches in the US market, and the increase in US market sales are major critical events that would highly influence Alkem’s future profitability.
- R&D Spending & Product Pipeline
Investors will want to know how much they are investing into the company, as well as how many new products the company is coming out with.
- Domestic Market Share & Brand Performance
The performance of prominent brands like Clavam, Pan-D, and Taxim-O within the Indian market will also be observed. The ability to gain market shares within the Indian pharmaceutical industry represents business stability.
Final Thoughts
Alkem Laboratories will announce its Q3 FY26 results on 13th February 2026. Analysts expect 1.18% revenue growth, a 9.12% fall in PAT, and a 0.03% fall in EBITDA. Alkem Laboratories focuses on revenue growth from order execution, margin improvement, the strength of the order book, and management.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
GOCL Corporation Q3 Results FY26 Preview
Godrej Industries Q3 Results FY26 Preview
Godawari Power and Ispat Q3 Results FY26 Preview
Himatsingka Seide Q3 Results FY26 Preview
Igarashi Motors India FY26 Preview
Related Posts
AYM Syntax Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
Asian Paints Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
Alicon Castalloy Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
Akums Drugs and Pharmaceuticals Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
